Efficacy and Safety Analysis of Simvastatin in Patients with Myocardial Infarction Undergoing Percutaneous Coronary Intervention

WANG Xiaomin; YANG Yajing

doi:10.14033/j.cnki.cfmr.2025.18.004

Abstract：Objective:To analyze and explore the efficacy and safety of simvastatin in patients with myocardial infarction undergoing percutaneous coronary intervention(PCI).Method:122 patients with myocardial infarction admitted to Hebei Chest Hospital from September 2022 to February 2024 were selected as the study objects.According to the random envelope drawing method,122 patients were divided into simvastatin group and atorvastatin group,with 61 cases in each group.Atorvastatin group was given atorvastatin treatment,simvastatin group was given simvastatin treatment,both groups were observed for 14 days,and clinical efficacy and follow-up safety were recorded.Result:After 14 days of treatment,the total effective rate of simvastatin group was higher than that of atorvastatin group,and the difference was statistically significant(P<0.05).The expression levels of serum C-reactive protein(CRP)and interleukin-6(IL-6)in both groups after 14 days of treatment were lower than those before treatment,and they were lower in Simvastation group simvastatin group were lower than those in atorvastatin group,with statistical significance(P<0.05).The left ventricular end-systolic diameter and left ventricular end-diastolic diameter of the two groups after 14 days of treatment were lower than those before treatment,and they were lower in Simvastation group,with statistical significance(P<0.05).After 6 months of follow-up,the incidence of major adverse cardiovascular events such as reinfarction,angina pectoris,heart failure and cardiac death in simvastatin group was lower than that in atorvastatin group,with statistical significance(P<0.05).Conclusion:Simvastatin used in patients with myocardial infarction can improve the therapeutic effect,inhibit the expression of inflammatory factors,and improve the left ventricular end-systolic diameter and left ventricular end-diastolic diameter of patients,thereby reducing the incidence of major cardiovascular adverse events during follow-up.